List of works - Pamela M. Pollock

High frequency of BRAF mutations in nevi

scientific article

Microarray expression profiling in melanoma reveals a BRAF mutation signature.

scientific article published on May 2004

Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells

scientific article published on July 2005

Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia

scientific article published in May 2003

Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma

scientific article

Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation

scientific article

Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative

scientific article published on 27 February 2015

Targeting mutant fibroblast growth factor receptors in cancer

scientific article published on March 2011

Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma

scientific article

Active Notch1 confers a transformed phenotype to primary human melanocytes

scientific article published on 23 June 2009

FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features

scientific article (publication date: 2012)

A genome-based strategy uncovers frequent BRAF mutations in melanoma

scientific article published in July 2002

Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status

scientific article published on 5 October 2012

A crystallographic snapshot of tyrosine trans-phosphorylation in action

scientific article

p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation

scientific article published on December 2010

A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.

scientific article

Analysis of the CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds

scientific article published on December 11, 1997

The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors

scientific article published on August 2013

Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition

scientific article published on 09 December 2016

Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk

scientific article

Osteopontin is a downstream effector of the PI3-kinase pathway in melanomas that is inversely correlated with functional PTEN.

scientific article published on 29 March 2006

FGFR2 mutations are rare across histologic subtypes of ovarian cancer

scientific article published on 27 January 2010

FGFR2 as a molecular target in endometrial cancer

scientific article published on February 2009

The Prognostic and Predictive Value of Melanoma-related MicroRNAs Using Tissue and Serum: A MicroRNA Expression Analysis

scientific article

Homodimerization Controls the Fibroblast Growth Factor 9 Subfamily's Receptor Binding and Heparan Sulfate-Dependent Diffusion in the Extracellular Matrix

scientific article

Cellular settings mediating Src Substrate switching between focal adhesion kinase tyrosine 861 and CUB-domain-containing protein 1 (CDCP1) tyrosine 734

scientific article published on 12 October 2011

XIAP downregulation accompanies mebendazole growth inhibition in melanoma xenografts

scientific article

Deletion mapping suggests that the 1p22 melanoma susceptibility gene is a tumor suppressor localized to a 9-mb interval

article

PTEN inactivation is rare in melanoma tumours but occurs frequently in melanoma cell lines

scientific article published in December 2002

CDKN2A is not the principal target of deletions on the short arm of chromosome 9 in neuroendocrine (Merkel cell) carcinoma of the skin

scientific article

Mutations in exon 3 of the β-catenin gene are rare in melanoma cell lines

scientific article published in April 2002

Mutation analysis of theCDKN2A promoter in Australian melanoma families

article

PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2mutant Endometrial Cancers

scientific article published on 23 January 2017

Lucky draw in the gene raffle

scientific article published in June 2002

Common variation in the fibroblast growth factor receptor 2 gene is not associated with endometriosis risk

scientific article

FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study

scientific article published on 15 March 2017

Fibroblast growth factor receptor inhibition synergizes with Paclitaxel and Doxorubicin in endometrial cancer cells

scientific article published in November 2012

Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A TransPORTEC initiative

scientific article

A Common Variant at the 14q32 Endometrial Cancer Risk Locus Activates AKT1 through YY1 Binding

scientific article published on June 2016

Paralog-Specific Kinase Inhibition of FGFR4: Adding to the Arsenal of Anti-FGFR Agents

scientific article

Loss of Rearranged L-Myc Fusion (RLF) results in defects in heart development in the mouse.

scientific article published on 5 December 2016

Endometrial cancer cells exhibit high expression of p110β and its selective inhibition induces variable responses on PI3K signaling, cell survival and proliferation

scientific article published on 16 December 2016

hSSB1 phosphorylation is dynamically regulated by DNA-PK and PPP-family protein phosphatases

scientific article published on 6 April 2017

The "melanoma-enriched" microRNA miR-4731-5p acts as a tumour suppressor

scientific article published on 16 June 2016

A homologue of the Drosophila Son of sevenless gene maps to mouse chromosome 17.

scientific article published in December 1993

Patient-derived xenograft models capture genomic heterogeneity in endometrial cancer

scientific article published on 10 January 2022

Lineage-specific biomarkers predict response to FGFR inhibition

scientific article published on December 2012

List of works by Pamela M. Pollock

High frequency of BRAF mutations in nevi

Microarray expression profiling in melanoma reveals a BRAF mutation signature.

Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells

Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia

Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma

Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation

Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative

Targeting mutant fibroblast growth factor receptors in cancer

Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma

Active Notch1 confers a transformed phenotype to primary human melanocytes

FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features

A genome-based strategy uncovers frequent BRAF mutations in melanoma

Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status

A crystallographic snapshot of tyrosine trans-phosphorylation in action

p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation

A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.

Analysis of the CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds

The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors

Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition

Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk

Osteopontin is a downstream effector of the PI3-kinase pathway in melanomas that is inversely correlated with functional PTEN.

FGFR2 mutations are rare across histologic subtypes of ovarian cancer

FGFR2 as a molecular target in endometrial cancer

The Prognostic and Predictive Value of Melanoma-related MicroRNAs Using Tissue and Serum: A MicroRNA Expression Analysis

Homodimerization Controls the Fibroblast Growth Factor 9 Subfamily's Receptor Binding and Heparan Sulfate-Dependent Diffusion in the Extracellular Matrix

Cellular settings mediating Src Substrate switching between focal adhesion kinase tyrosine 861 and CUB-domain-containing protein 1 (CDCP1) tyrosine 734

XIAP downregulation accompanies mebendazole growth inhibition in melanoma xenografts

Deletion mapping suggests that the 1p22 melanoma susceptibility gene is a tumor suppressor localized to a 9-mb interval

PTEN inactivation is rare in melanoma tumours but occurs frequently in melanoma cell lines

CDKN2A is not the principal target of deletions on the short arm of chromosome 9 in neuroendocrine (Merkel cell) carcinoma of the skin

Mutations in exon 3 of the β-catenin gene are rare in melanoma cell lines

Mutation analysis of theCDKN2A promoter in Australian melanoma families

PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2mutant Endometrial Cancers

Lucky draw in the gene raffle

Common variation in the fibroblast growth factor receptor 2 gene is not associated with endometriosis risk

FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study

Fibroblast growth factor receptor inhibition synergizes with Paclitaxel and Doxorubicin in endometrial cancer cells

Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A TransPORTEC initiative

A Common Variant at the 14q32 Endometrial Cancer Risk Locus Activates AKT1 through YY1 Binding

Paralog-Specific Kinase Inhibition of FGFR4: Adding to the Arsenal of Anti-FGFR Agents

Loss of Rearranged L-Myc Fusion (RLF) results in defects in heart development in the mouse.

Endometrial cancer cells exhibit high expression of p110β and its selective inhibition induces variable responses on PI3K signaling, cell survival and proliferation

hSSB1 phosphorylation is dynamically regulated by DNA-PK and PPP-family protein phosphatases

The "melanoma-enriched" microRNA miR-4731-5p acts as a tumour suppressor

A homologue of the Drosophila Son of sevenless gene maps to mouse chromosome 17.

Patient-derived xenograft models capture genomic heterogeneity in endometrial cancer

Lineage-specific biomarkers predict response to FGFR inhibition